{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:32:01Z","timestamp":1792427521859,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.jaad.2014.03.019","type":"journal-article","created":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T01:32:16Z","timestamp":1398907936000},"page":"787-794","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":207,"title":["Chemotherapy-induced hand-foot syndrome and\u00a0nail\u00a0changes: A review of clinical presentation, etiology, pathogenesis, and management"],"prefix":"10.1016","volume":"71","author":[{"given":"Kristen K.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loren","family":"Gorcey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth N.","family":"McLellan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2014.03.019_bib1","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000251603","article-title":"Erythematous eruption of the palms and soles associated with mitotane therapy","volume":"148","author":"Zuehlke","year":"1974","journal-title":"Dermatologica"},{"key":"10.1016\/j.jaad.2014.03.019_bib2","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/00001622-200203000-00012","article-title":"Cutaneous toxicities of cancer therapy","volume":"14","author":"Alley","year":"2002","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.jaad.2014.03.019_bib3","first-page":"652","article-title":"The hand-foot-syndrome associated with medical tumor therapy\u2013classification and management","volume":"8","author":"Degen","year":"2010","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.jaad.2014.03.019_bib4","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00128071-200001040-00004","article-title":"Antineoplastic therapy-induced palmar plantar erythrodysesthesia (\u2018hand-foot\u2019) syndrome: incidence, recognition and management","volume":"1","author":"Nagore","year":"2000","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2014.03.019_bib5","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000258880","article-title":"Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib","volume":"77","author":"Lipworth","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.jaad.2014.03.019_bib6","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1093\/annonc\/mdr580","article-title":"Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib","volume":"23","author":"Dranitsaris","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2014.03.019_bib7","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0190-9622(91)70073-B","article-title":"Chemotherapy-induced acral erythema","volume":"24","author":"Baack","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.03.019_bib8","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jaad.2008.05.018","article-title":"Toxic erythema of chemotherapy: a useful clinical term","volume":"59","author":"Bolognia","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.03.019_bib9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000327767","article-title":"Palmar-plantar erythrodysesthesia associated with chemotherapy and its treatment","volume":"4","author":"Farr","year":"2011","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.jaad.2014.03.019_bib10","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/01.cnd.0000211401.19995.a2","article-title":"Small-fiber neuropathy associated with capecitabine (Xeloda)-induced hand-foot syndrome: a case report","volume":"7","author":"Stubblefield","year":"2006","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1016\/j.jaad.2014.03.019_bib11","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1634\/theoncologist.2011-0033","article-title":"HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome","volume":"16","author":"Sibaud","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.jaad.2014.03.019_bib12","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1001\/archdermatol.2011.320","article-title":"Capecitabine-induced hand-foot syndrome complicated by pseudomonal superinfection resulting in bacterial sepsis and death: case report and review of the literature","volume":"147","author":"Hoesly","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2014.03.019_bib13","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ejca.2008.01.028","article-title":"Pegylated\u00a0liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts","volume":"44","author":"von Moos","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaad.2014.03.019_bib14","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events v4.0. NCI, NIH, DHHS. May 29, 2009 NIH publication # 09-7473."},{"key":"10.1016\/j.jaad.2014.03.019_bib15","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1248\/bpb.35.717","article-title":"Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer","volume":"35","author":"Azuma","year":"2012","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.jaad.2014.03.019_bib16","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/annonc\/mdp278","article-title":"Travel warning with capecitabine","volume":"20","author":"Wong","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2014.03.019_bib17","first-page":"2307","article-title":"The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia","volume":"29","author":"Martschick","year":"2009","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jaad.2014.03.019_bib18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s13577-012-0057-0","article-title":"Pathogenesis of hand-foot syndrome induced by PEG-modified liposomal doxorubicin","volume":"26","author":"Yokomichi","year":"2013","journal-title":"Hum Cell"},{"key":"10.1016\/j.jaad.2014.03.019_bib19","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1158\/1078-0432.CCR-08-1141","article-title":"Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy","volume":"15","author":"Azad","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2014.03.019_bib20","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1365-2125.2008.03159.x","article-title":"Candidate mechanisms for capecitabine-related hand-foot syndrome","volume":"66","author":"Milano","year":"2008","journal-title":"Br\u00a0J Clin Pharmacol"},{"key":"10.1016\/j.jaad.2014.03.019_bib21","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1158\/1078-0432.CCR-10-1741","article-title":"A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome","volume":"17","author":"Caronia","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2014.03.019_bib22","doi-asserted-by":"crossref","first-page":"5491","DOI":"10.1158\/1078-0432.CCR-06-0747","article-title":"Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians","volume":"12","author":"Mattison","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2014.03.019_bib23","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1517\/14740338.2011.546342","article-title":"Capecitabine and hand-foot syndrome","volume":"10","author":"Saif","year":"2011","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jaad.2014.03.019_bib24","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s10637-013-9927-x","article-title":"The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis","volume":"31","author":"Fischer","year":"2013","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jaad.2014.03.019_bib25","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.4008","article-title":"A randomized controlled phase II study of the prophylactic effect of urea-based cream on the hand-foot skin reaction associated\u00a0with sorafenib in advanced hepatocellular carcinoma [abstract]","author":"Ren","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2014.03.019_bib26","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.9059","article-title":"Prevention of palmoplantar erythrodysesthesia (PPE) with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (PLD), a placebo-controlled, double blinded, phase III trial (SAKK 92\/08) [abstract]","author":"Ruhstaller","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2014.03.019_bib27","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ygyno.2007.10.021","article-title":"Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling","volume":"108","author":"Mangili","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jaad.2014.03.019_bib28","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/cncr.23333","article-title":"Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot","volume":"112","author":"Scott\u00e9","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2014.03.019_bib29","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1200\/JCO.2005.15.651","article-title":"Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand","volume":"23","author":"Scotte","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2014.03.019_bib30","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/annonc\/mdr400","article-title":"Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial","volume":"23","author":"Zhang","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2014.03.019_bib31","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/bjc.2012.318","article-title":"A randomized study evaluating the use of pyridoxine to avoid capecitabine dose modifications","volume":"107","author":"Corrie","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jaad.2014.03.019_bib32","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1200\/JCO.2010.29.1807","article-title":"Pyridoxine is not effective to\u00a0prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study","volume":"28","author":"Kang","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2014.03.019_bib33","doi-asserted-by":"crossref","first-page":"4735","DOI":"10.1002\/cncr.25262","article-title":"A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients","volume":"116","author":"von Gruenigen","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2014.03.019_bib34","first-page":"907","article-title":"Efficacy of a protocol including\u00a0heparin ointment for treatment of multikinase inhibitor-induced hand-foot skin reactions","volume":"21","author":"Li","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jaad.2014.03.019_bib35","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/01.coc.0000026486.56886.18","article-title":"Cutaneous hand and foot toxicity associated with cancer chemotherapy","volume":"26","author":"Childress","year":"2003","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jaad.2014.03.019_bib36","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/annonc\/mdg050","article-title":"Taxane-induced nail changes: incidence, clinical presentation and outcome","volume":"14","author":"Minisini","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2014.03.019_bib37","first-page":"1191","article-title":"Nail changes due to docetaxel\u2013a neglected side effect and nuisance for the patient","volume":"15","author":"Winther","year":"2007","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jaad.2014.03.019_bib38","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/S0140-6736(00)04210-0","article-title":"Clinical picture: nail changes secondary to docetaxel","volume":"357","author":"Wasner","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2014.03.019_bib39","first-page":"203","article-title":"Idarubicin-induced pigmentary changes of the nails","volume":"59","author":"Borecky","year":"1997","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2014.03.019_bib40","first-page":"317","article-title":"Nail hyperpigmentation secondary to therapy with doxorubicin","volume":"135","author":"Giacobetti","year":"1981","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.jaad.2014.03.019_bib41","first-page":"909","article-title":"Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors","volume":"20","author":"Peuvrel","year":"2012","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jaad.2014.03.019_bib42","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2014.03.019_bib43","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s10637-011-9652-2","article-title":"The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis","volume":"30","author":"Balagula","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jaad.2014.03.019_bib44","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicenter, randomized, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2014.03.019_bib45","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdt015","article-title":"Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients","volume":"24","author":"Boussemart","year":"2013","journal-title":"Ann Oncol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962214012468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962214012468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:32:47Z","timestamp":1759271567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962214012468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0190962214012468"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2014.03.019","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemotherapy-induced hand-foot syndrome and\u00a0nail\u00a0changes: A review of clinical presentation, etiology, pathogenesis, and management","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2014.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}